INM004
- Generic Name
- INM004
- Drug Type
- Biotech
- Background
INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.
Efficacy of INM004 in Children With STEC-HUS
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Inmunova S.A.
- Target Recruit Count
- 220
- Registration Number
- NCT06389474
- Locations
- 🇦🇷
Hospital Interzonal Dr. José Penna, Bahia Blanca, Buenos Aires, Argentina
🇦🇷Hospital de niños Sor MarÃa Ludovica, La Plata, Buenos Aires, Argentina
🇦🇷Clinica del niño y la madre, Mar Del Plata, Buenos Aires, Argentina
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
- Conditions
- Pediatric Kidney DiseaseHemolytic-Uremic SyndromeDiarrhea-Associated Hemolytic Uremic Syndrome
- Interventions
- Other: SoC
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Inmunova S.A.
- Target Recruit Count
- 57
- Registration Number
- NCT05569746
- Locations
- 🇦🇷
Hospital Interzonal Especializado Materno Infantil Don Victorio Tetamanti, Mar Del Plata, Buenos Aires, Argentina
🇦🇷Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén, Argentina
🇦🇷Sanatorio de Niños, Rosario, Santa Fe, Argentina
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
- Conditions
- STEC, UnspecifiedHemolytic-Uremic SyndromeBloody DiarrheaPediatric Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Inmunova S.A.
- Target Recruit Count
- 11
- Registration Number
- NCT04132375
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina
🇦🇷Hospital Orlando Alassia, Santa Fe, Argentina
🇦🇷Hospital Castro Rendon, Neuquén, Neuquen, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.